SuperworthCorvus Pharmaceuticals CRVS
- Market cap
- $885.8M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- not a meaningful number
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- not a meaningful number
- Net margin
- n/m
- not a meaningful number
- Free cash flow yield
- −5.1%
Corvus Pharmaceuticals' trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D | $4M−62% | $4M−2% | $4.1M−11% | $4.1M+4% | $5.2M+32% | $6M+49% | $7.5M+83% | $7.9M+91% | $8.5M+62% | $9.9M+66% | $11.2M+50% | $16M+103% |
| SG&A | $1.6M−24% | $1.7M+4% | $2.2M+10% | $1.8M+10% | $2M+28% | $2.1M+29% | $2.5M+13% | $2.4M+31% | $2.1M+4% | $2.3M+7% | $3.7M+50% | $3.3M+40% |
| −$5.6M−55% | −$5.7M−0% | −$6.3M−5% | −$5.9M+6% | −$7.3M+31% | −$8.1M+43% | −$9.9M+59% | −$10.3M+73% | −$10.6M+46% | −$12.2M+51% | −$14.9M+50% | −$19.3M+88% | |
| Pre-tax income | −$5.1M | −$5.2M | −$5.9M−3% | −$3.7M−29% | −$39.5M+670% | −$9.9M+89% | $15.7M | −$7.6M+107% | −$9.8M−75% | −$11.6M+17% | −$13.1M | −$17.3M+127% |
| Net income | −$6M−60% | −$6.7M−32% | −$5.7M−28% | −$4.3M−35% | −$40.2M+570% | −$12.1M+82% | $15.2M | −$8M+88% | −$10.2M−75% | −$12.3M+2% | −$13.7M | −$18M+125% |
| −$0.12−63% | −$0.14−33% | −$0.12−29% | −$0.07−50% | −$0.60+400% | −$0.18+29% | −$0.13+8% | −$0.10+43% | −$0.12−80% | −$0.15−17% | −$0.15+15% | −$0.19+90% | |
| 49M+5% | 49M+5% | 49M+5% | 59.7M+26% | 66.7M+36% | 68.3M+39% | 75.2M+53% | 77.8M+30% | 82.8M+24% | 83M+21% | 90M+20% | 92.4M+19% |
EPS, diluted: 7 periods, Q4 FY15 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 10 periods, Q4 FY15 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY20: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Corvus Pharmaceuticals' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| CRVSCorvus Pharmaceuticals | $885.8M | n/m | n/a | n/m | n/m | n/m | |
| ABUSArbutus Biopharma | $831M | 5.4× | 5.6× | 4.6× | n/m | 84.2% | |
| COLLCollegium Pharmaceutical | $747.5M | 18.5× | 19.1× | 0.9× | +14% | 5.9% | |
| AMPHAmphastar Pharmaceuticals | $1.1B | 14.8× | 20.6× | 1.5× | +1% | 10.8% | |
| OMEROmeros | $1.2B | 10.9× | 11.7× | n/m | n/m | n/m | |
| CRMDCorMedix | $611.9M | 3.7× | 4.0× | 1.3× | +281% | 40.5% | |
| ZVRAZevra Therapeutics | $582.6M | 10.5× | 12.3× | 4.3× | +119% | 42.8% | |
| IRWDIronwood Pharmaceuticals | $571.7M | 4.5× | 14.9× | 1.5× | +26% | 33.4% | |
| PBYIPuma Biotechnology | $568.9M | 21.2× | 12.3× | 2.5× | −3% | 11.6% | |
| PCRXPacira BioSciences | $1.5B | 104× | 65.6× | 1.9× | +6% | 2.0% | |
| ANABAnaptysbio | $1.5B | 10.7× | 100.0× | n/m | n/m | n/m | |
| Peer median | $789.2M | 10.8× | 13.6× | 1.7× | +14% | 22.5% |
More on Corvus Pharmaceuticals
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .